Market Research Logo

Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies

Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies

Alzheimer’s Disease Market in Asia-Pacific to Surpass $5 Billion by 2021, says GBI Research

The Asia-Pacific (APAC) Alzheimer’s disease market will grow from $3 billion in 2014 to $5.1 billion in 2021, representing a robust Compound Annual Growth Rate of 7.9%, according to business intelligence provider GBI Research.

The company’s latest report* states that the main driver of this impressive growth, which will occur across the APAC countries of India, China, Australia and Japan, will be rising and aging populations, as Alzheimer’s disease is significantly more prevalent among the elderly.

Additional market drivers include better diagnostic techniques, improving health awareness, special healthcare programs, health insurance coverage, and increasing treatment affordability.

Gayathri Kanika, Analyst for GBI Research, says: “An example of healthcare reforms is the Japanese government’s recently approved plan to increase the number of nurses and care workers in the country’s healthcare system by 2025, in order to help patients access and interpret information about their health, thereby improving knowledge and diagnoses of Alzheimer’s.

“Across the APAC region, the expansion of health insurance coverage will increase access to healthcare, also leading to a rise in Alzheimer’s diagnosis and higher treatment rates.”

In terms of the current Alzheimer’s pipeline, there are a number of late-stage products with the potential to be approved and launched in APAC countries during the forecast period. These include first-in-class Beta-site Amyloid precursor protein Cleaving Enzyme (BACE)1 inhibitors and passive immunotherapies.

Gayathri explains: “Three important anti-beta Amyloid (Aβ) drugs are Roche’s gantenerumab, TauRX Therapeutics’ LMTX and Merck’s MK-8931 (verubecestat), which are in Phase III development in Australia and Japan, and will capture significant market share in these countries after they are launched late in the forecast period.

“Acetylcholinesterase Inhibitors (AChEIs), such as Eisai’s Aricept (donepezil), Novartis’ Exelon (rivastigmine) and Janssen’s Razadyne (galantamine), will also continue to capture major patient share across all Alzheimer’s sub-populations in the four APAC countries.”

Despite the success of these treatments, GBI Research states that significant unmet needs will remain for Alzheimer’s patients as there are only a few disease modifying therapies in the late stage pipeline, with currently available therapies only able to treat symptoms of the disease rather than preventing or slowing its progression.

*Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies

This report provides analysis of the Alzheimer’s disease treatment space across the Asia-Pacific countries of India, China, Australia and Japan, with annualized market date from 2014 and forecast to 2021. It includes analysis of the Alzheimer’s disease pipeline stratified by stage of development, molecule type, and molecular target.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.5 Diagnosis
2.6 Disease Stages
2.7 Prognosis
2.8 Treatment Options
2.8.1 Treatment Algorithm
2.8.2 Pharmacological Treatments
2.8.3 Non-pharmacological Treatments
3 Marketed Products
3.1 Overview
3.2 Acetylcholinesterase Inhibitors
3.2.1 Aricept (donepezil) - Eisai
3.2.2 Exelon (rivastigmine) - Novartis
3.2.3 Razadyne (galantamine) - Janssen
3.2.4 Cognex (tacrine) - Shionogi
3.3 NMDA Receptor Antagonists
3.3.1 Namenda/Ebixa/Axura/Abixa (Memantine), Merz/Lundbeck/Forest/Daiichi Sankyo
3.4 AChEI and NMDA Receptor Antagonists
3.4.1 Namzaric (memantine ER + donepezil), Actavis and Adamas
3.5 Heat Map - Marketed Products Overview
4 Pipeline Analysis
4.1 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.2 Pipeline Analysis by Mechanism of Action
4.3 Promising Pipeline Candidates
4.3.1 MK-8931- Merck
4.3.2 LMTX (methylthioninium chloride) - TauRX Therapeutics
4.3.3 Gantenerumab (RG-1540) - Roche
4.3.4 AZD3293 - AstraZeneca
4.3.5 AB1010 (masitinib) - AB Science
4.3.6 BIIB037 - Biogen
4.3.7 TTP488 - vTv Therapeutics
4.3.8 EVP-6124 - FORUM Pharmaceuticals
4.3.9 Lu AE58054 - Lundbeck
4.3.10 Sodium Oligomannurarate
4.4 Heat Map for Pipeline Products
5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Size
5.2.1 Patient Enrollment per Product by Stage of Development by Molecule Type and Molecular Target
5.2.2 Patient Enrollment per Trial by Stage of Development by Molecule Type and Molecular Target
5.3 Clinical Trial Duration
5.3.1 Trial Duration by Stage of Development and Molecule Type
5.3.2 Trial Duration by Stage of Development and Molecular Target
5.4 Summary of Clinical Trial Metrics
6 Multi-Scenario Forecast
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 Japan
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
7 Drivers and Barriers
7.1 Drivers
7.1.1 Rising Prevalence
7.1.2 Increasing Healthcare Reforms for Elderly Population
7.1.3 Increasing Health Insurance Coverage for Aged Population
7.1.4 Increasing Public and Policy-Maker Awareness
7.1.5 Greater Focus on Prodromal and Presymptomatic AD
7.2 Barriers
7.2.1 High Rate of Clinical Trial Failure
7.2.2 Impending Patent Cliffs and Generic Erosion
7.2.3 Drug Testing in Patients with Established AD and Advanced Neurodegeneration
7.2.4 Low Diagnosis and Treatment Rate
7.2.5 Additional Competition from Traditional Medicines
8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.4 Key Co-development Deals
9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 Phase I
9.1.4 Phase II
9.1.5 Phase III
9.2 Market Forecasts to 2021
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis
9.6 Contact Us
9.7 Disclaimer
1.1 List of Tables
Table 1: AD Market, Symptoms of AD at Different Stages of Disease
Table 2: AD Market, Symptoms of Mid Cognitive Impairment
Table 3: AD Market, Mini Mental State Exam
Table 4: AD Market, Alzheimer’s Disease Assessment Scale Cognitive Subscale
Table 5: AD Market, Mild Cognitive Impairment Diagnosis Guidelines
Table 6: AD Market, Global Deterioration Scale for AD
Table 7: AD Market, Management of AD Symptoms
Table 8: AD Market, Global, Pipeline Products, Discovery, 2016
Table 9: AD Market, Global, Pipeline Products, Preclinical, 2016
Table 10: AD Market, Global, Pipeline Products, Phase I, 2016
Table 11: AD Market, Global, Pipeline Products, Phase II, 2016
Table 12: AD Market, Global, Pipeline Products, Phase III, 2016
Table 13: MCI Market, Asia-Pacific, Market Forecast, 2014-2021
Table 14: AD Market, Asia-Pacific, Market Forecast, 2014-2021
Table 15: AD and MCI Combined Market, Asia-Pacific, Market Forecast, 2014-2021
Table 16: MCI Market, India, Market Forecast, 2014-2021
Table 17: AD Market, India, Market Forecast, 2014-2021
Table 18: AD and MCI Combined Market, India, Market Forecast, 2014-2021
Table 19: MCI Market, China, Market Forecast, 2014-2021
Table 20: AD Market, China, Market Forecast, 2014-2021
Table 21: AD and MCI Combined Market, China, Market Forecast, 2014-2021
Table 22: MCI Market, Australia, Market Forecast, 2014-2021
Table 23: AD Market, Australia, Market Forecast, 2014-2021
Table 24: AD and MCI Combined Market, Australia, Market Forecast, 2014-2021
Table 25: MCI Market, Japan, Market Forecast, 2014-2021
Table 26: AD Market, Japan, Market Forecast, 2014-2021
Table 27: MCI and AD Combined Market, Japan, Market Forecast, 2014-2021
1.2 List of Figures
Figure 1: AD Market, Treatment Algorithm of AD
Figure 2: AD Market, Heat Map for Marketed Products
Figure 3: AD Market, Overall Pipeline
Figure 4: AD Market, Pipeline by Mechanism of Action (%)
Figure 5: AD Market, Asia-Pacific, Verubecestat Market Forecast ($m), 2020-2021
Figure 6: AD Market, Asia-Pacific, LMTX Market Forecast ($m), 2018-2021
Figure 7: AD Market, Asia-Pacific, Gantenerumab Market Forecast ($m), 2020-2021
Figure 8: AD Market, Heat Map for Pipeline Products
Figure 9: AD Market, Clinical Trial Failure Rates by Phase (%)
Figure 10: AD Market, Clinical Trial Failure Rates by Molecular Target (%)
Figure 11: AD Market, Clinical Trial Size per Product by Molecule Type (participants)
Figure 12: AD Market, Clinical Trial Size per Product by Molecular Target (participants)
Figure 13: AD Market, Clinical Trial Size per Trial by Molecule Type (participants)
Figure 14: AD Market, Clinical Trial Size per Trial by Molecular Target (participants)
Figure 15: AD Market, Clinical Trial Duration by Molecule Type (months)
Figure 16: AD Market, Clinical Trial Duration by Molecular Target (months)
Figure 17: AD Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 18: AD Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 19: AD and MCI Market, Asia-Pacific, Treatment Patterns (million), 2014-2021
Figure 20: AD and MCI Combined Market, Asia-Pacific, Treatment Patterns (million), 2014-2021
Figure 21: AD and MCI Market, Asia-Pacific, Market Size ($bn), 2014-2021
Figure 22: AD and MCI Combined Market, Asia-Pacific, Market Size ($bn), 2014-2021
Figure 23: AD and MCI Market, India, Treatment Patterns (million), 2014-2021
Figure 24: AD and MCI Combined Market, India, Treatment Patterns (million), 2014-2021
Figure 25: AD and MCI Market, India, Annual Cost of Therapy ($), 2014-2021
Figure 26: AD and MCI Market, India, Market Size ($m), 2014-2021
Figure 27: AD and MCI Combined Market, India, Market Size ($m), 2014-2021
Figure 28: AD and MCI Market, China, Treatment Patterns (million), 2014-2021
Figure 29: AD and MCI Combined Market, China, Treatment Patterns (million), 2014-2021
Figure 30: AD and MCI Market, China, Annual Cost of Therapy ($), 2014-2021
Figure 31: AD and MCI Market, China, Market Size ($m), 2014-2021
Figure 32: AD and MCI Combined Market, China, Market Size ($m), 2014-2021
Figure 33: AD and MCI Market, Australia, Treatment Patterns (‘000), 2014-2021
Figure 34: AD and MCI Combined Market, Australia, Treatment Patterns (‘000), 2014-2021
Figure 35: AD and MCI Market, Australia, Annual Cost of Therapy ($), 2014-2021
Figure 36: AD and MCI Market, Australia, Market Size ($m), 2014-2021
Figure 37: AD and MCI Combined Market, Australia, Market Size ($m), 2014-2021
Figure 38: AD and MCI Market, Japan, Treatment Patterns (million), 2014-2021
Figure 39: AD and MCI Combined Market, Japan, Treatment Patterns (million), 2014-2021
Figure 40: AD and MCI Market, Japan, Annual Cost of Therapy ($), 2014-2021
Figure 41: AD and MCI Market, Japan, Market Size ($m), 2014-2021
Figure 42: AD and MCI Combined Market, Japan, Market Size ($bn), 2014-2021
Figure 43: AD Market, Licensing Deals by Value, 2006-2015
Figure 44: AD Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2015
Figure 45: AD Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2015
Figure 46: AD Market, Global, Licensing Deals by Molecule Type and Value, 2006-2015
Figure 47: AD Market, Global, Licensing Deals by Molecular Target and Aggregate Value, 2006-2015
Figure 48: AD Market, Global, Co-development Deals by Value, 2006-2015
Figure 49: AD Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2015
Figure 50: AD Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2015
Figure 51: AD Market, Global, Co-development Deals by Molecule Type and Value, 2006-2015
Figure 52: AD Market, Global, Licensing Deals by Molecular Target and Aggregate Value, 2006-2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report